Immix Biopharma (IMMX) EBITDA (2021 - 2026)

Immix Biopharma has reported EBITDA for 6 years, with the latest figure at -$10.8 million in Q1 2026.

• Quarterly EBITDA fell 130.71% year-over-year to -$10.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.1 million (down 65.74% YoY) and the FY2025 annual result came in at -$30.0 million, down 32.11% from the prior year.
• EBITDA rose to -$10.8 million in Q1 2026 per IMMX's latest filing, from -$10.9 million in the prior quarter.
• Over five years, EBITDA peaked at -$1.3 million in Q1 2022 and troughed at -$10.9 million in Q4 2025.
• A 5-year average of -$5.2 million and a median of -$4.7 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2025: EBITDA tumbled 718.38% in 2022, then gained 16.23% in 2025.
• Over 5 years, EBITDA stood at -$3.8 million in 2022, then sank by 41.67% to -$5.4 million in 2023, then increased by 7.23% to -$5.0 million in 2024, then tumbled by 118.43% to -$10.9 million in 2025, then increased by 0.82% to -$10.8 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$10.8 million, -$10.9 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.